BPC-157 reconstitution calculator

Enter your vial amount and target dose. DrawDose returns the BAC water volume, syringe units, and a vial label you can copy.

Quick answer for the most common vial sizes

The 2 mL : 5 mg ratio documented across compounding pharmacy formulation guides and community protocol references for BPC-157 produces a 2.5 mg/mL concentration, where 250 mcg draws as 10 units on a 1 mL insulin syringe.

The math holds at any concentration. DrawDose accepts any vial size and any BAC water volume and returns the correct syringe draw for the dose entered.

How to reconstitute lyophilized BPC-157

The procedure follows the standard sterile-injection prep workflow documented in compounding pharmacy formulation guides and peptide stability literature.

Bring the vial and BAC water to room temperature for 15 to 20 minutes before mixing. Cold liquid hitting cold powder slows dissolution and increases the chance of clumping. Wipe both vial tops with an alcohol swab and let them dry. Draw the BAC water into a 1 mL syringe.

Insert the needle into the BPC-157 vial at an angle so the water runs down the inside wall, not directly onto the powder pellet. Direct impingement on lyophilized peptide generates foam and can affect peptide structure. Once the water is in, swirl the vial gently for 20 to 30 seconds. Do not shake. BPC-157 dissolves quickly and produces a clear, colorless solution; cloudiness or particulate that does not clear within a minute indicates either incomplete dissolution or a sourcing concern.

Why concentration determines syringe units, not vial size

The relationship between vial size, BAC water, and syringe draw is fixed by concentration math. A 5 mg vial with 2 mL of water gives 2.5 mg/mL — every 10 units delivers 250 mcg. The same 5 mg vial with 5 mL of water gives 1 mg/mL, where 10 units delivers only 100 mcg. To hit a 250 mcg target dose with the second mix, the draw is 25 units instead of 10.

Standard reconstitution practice keeps the draw between 5 and 25 units on a 1 mL insulin syringe for sub-milligram peptides. That's the range where the tick marks are visually distinct and minor variation in the draw doesn't materially change the delivered dose. DrawDose computes this automatically; the auto-selected BAC water volume on the result panel is always tuned to keep the draw in that band.

Documented dosing protocols

BPC-157 is not FDA-approved, so no manufacturer prescribing information exists. Dosing references come from peer-reviewed preclinical research and community protocol surveys, both with explicit limitations on translation to human use.

The 2025 systematic review by Vasireddi et al. published in HSS Journal screened 544 articles from 1993 to 2024 and identified one human clinical study and 35 preclinical animal studies. Per the review, animal study doses for tendon and ligament healing were typically 10 mcg per kilogram bodyweight administered subcutaneously or intraperitoneally. Allometric scaling to a 70 kg human approximates 250 to 500 mcg, though the review explicitly notes that interspecies pharmacokinetic translation is not validated and human clinical safety data was not found.

Community protocol surveys aggregated from r/Peptides, r/PeptideHowTo, and r/BPC157 describe a typical dose range of 200 to 500 mcg per day administered subcutaneously, with 250 mcg starting and 500 mcg as the most commonly reported effective dose. Some protocols split the daily dose into two injections 12 hours apart; others use single daily administration. Higher protocols documented in community surveys reach 1,000 mcg per day, generally for the first weeks of acute injury recovery before stepping back to maintenance ranges.

The honest framing is that no human clinical trial data establishes a safe and effective dose. The ranges above describe what users and prescribers in compounded peptide practice have settled on; they do not represent regulatory-grade evidence.

Cycle length and on-off patterns

Community protocol surveys and clinician-published guides describe BPC-157 cycles ranging from 4 to 12 weeks of daily administration, often followed by an off period of similar length before resuming. The Huberman protocol cited across community references runs 8 weeks on, followed by 8 to 10 weeks off.

The rationale for cycling is not established in clinical literature. Proponents argue that cycling allows endogenous healing pathways to integrate the peptide's effects without continuous exogenous signaling. The Vasireddi review describes preclinical use of continuous administration in animal models without documented adverse effects, and notes that long-term human safety data is absent.

Acute injury recovery protocols commonly run shorter cycles (4 to 6 weeks) at higher doses; chronic recovery and gut-related applications run longer cycles (8 to 12 weeks) at standard doses.

Site-specific injection patterns

Per the preclinical literature reviewed by Vasireddi et al., subcutaneous injection of BPC-157 produces systemic distribution regardless of injection site. Animal studies showing tendon and ligament healing benefit injected the peptide both at the injury site and at distant sites, with healing effects observed in both protocols.

Community practice, documented across protocol surveys, commonly injects BPC-157 subcutaneously as close to the injury site as anatomically feasible for localized injury work. For systemic applications (gut healing, general recovery, anti-inflammatory protocols), abdominal subcutaneous injection 2 inches lateral to the umbilicus is the standard reference site. Both routes appear in peer-reviewed protocols.

Intramuscular injection is documented in some protocols, though subcutaneous is more common in community practice and accounts for the majority of preclinical research administration routes.

BPC-157 Acetate vs BPC-157 Arginate

Two salt forms of BPC-157 are commercially available and behave differently in the gastrointestinal tract.

BPC-157 Acetate is the conventional form used in injectable preparations. Per He et al. 2022, oral bioavailability of the acetate form in rats is approximately 3%, reflecting degradation by gastric acid and first-pass hepatic metabolism. Despite the low systemic bioavailability, the acetate form delivers a meaningful local dose to the gastrointestinal mucosa, which is relevant for gut-targeted applications.

BPC-157 Arginate is an arginine salt formulation. Per Diagen patent literature (WO2014142764A1), the arginate form claims oral bioavailability near 90% by buffering the peptide against gastric acid degradation. Independent peer-reviewed pharmacokinetic confirmation of this figure in humans is not yet published. The mechanism (pH-buffered salt protection) is pharmacologically plausible. The 15-amino-acid peptide sequence is identical between forms; the salt counter-ion is what differs.

For injectable use, the acetate form is the standard and is what most reconstitution protocols and animal studies reference. The arginate form is used primarily for oral applications where gastric stability matters.

Adverse reactions and safety profile

Per the Vasireddi et al. systematic review, no human clinical safety data was found across the 544 articles screened. Animal studies in the included preclinical literature describe no lethal dose established and a wide therapeutic window without documented adverse effects in the tested ranges.

Community protocol surveys describe BPC-157 as well-tolerated at standard ranges (200 to 500 mcg per day), with the most commonly reported events being mild injection-site reactions (transient redness, soreness) and occasional reports of mild fatigue, lightheadedness, or nausea, generally resolving without intervention. These reports are unverified and uncontrolled.

The honest framing is that BPC-157 has not been evaluated by the FDA for safety in any indication. Long-term human safety data does not exist. Theoretical concerns documented in the literature include effects on angiogenesis (which could theoretically affect tumor vascularization in undiagnosed malignancies) and unstudied interactions with other medications. Users with cancer history or immunocompromised conditions should not assume safety based on community reports.

WADA prohibited status

BPC-157 is on the World Anti-Doping Agency Prohibited List under category S0 (non-approved substances). Per WADA's banned-substances framework, athletes subject to anti-doping testing should not use BPC-157 at any time, in or out of competition. Detection methods for synthetic peptides have improved substantially since 2022; assuming non-detectability is no longer reliable.

This does not affect non-athlete users from a regulatory standpoint, but is worth flagging since BPC-157 is widely used in athletic recovery contexts where the WADA implications are direct.

Common reconstitution errors

Compounded peptide forums and pharmacy QA literature document a recurring set of errors specific to user-reconstituted BPC-157.

Drawing too small a volume on too large a syringe. A 250 mcg dose at 2.5 mg/mL is 10 units on a 1 mL insulin syringe. Some users default to 1 mL syringes regardless of draw volume; for sub-milligram doses, a 0.3 mL (30-unit) insulin syringe gives much better visual precision on small draws.

Reusing reconstituted vials beyond 28 days. The benzyl alcohol preservative in BAC water keeps reconstituted BPC-157 stable for approximately 28 days at 2 to 8°C per peptide stability literature. After that, peptide degradation accelerates and concentration drift becomes meaningful for sub-milligram dosing.

Switching between BPC-157 Acetate and BPC-157 Arginate without recalculating concentration. The two salts have slightly different molecular weights, which affects the actual peptide content per labeled milligram. Verify the label form and the COA-reported peptide content before switching.

Storing reconstituted vials in the refrigerator door. Door storage cycles through temperature variation each time the door opens. The back of the main compartment is the documented recommendation in peptide stability literature.

Storage and shelf life

Per peptide stability literature, reconstituted BPC-157 stays stable for approximately 28 days at 2 to 8°C (36 to 46°F) when reconstituted with bacteriostatic water containing benzyl alcohol preservative. Some conservative protocols specify 14 to 21 days as a more cautious window for sub-milligram dosing where concentration drift matters more.

Lyophilized BPC-157 stores for 24 months or longer at -20°C and 12 months or longer at 2 to 8°C, per the same stability literature. The peptide is notably stable in its lyophilized state compared to many synthetic peptides.

Heat exposure during shipping is the most documented threat to potency. Orders placed in summer months commonly arrive with insulated cold packs; visibly warm packages on arrival warrant a sourcing follow-up before reconstitution.

What to verify on a Certificate of Analysis

The COA reports the actual peptide content of a specific lot. Net peptide weight is the measured milligrams of peptide in the vial, separate from any excipients (mannitol, sodium chloride) included for stability. Purity by HPLC reflects the percentage of UV-absorbing material that is the target peptide; 95% is the research-grade minimum the peptide industry has converged on, and 98% is the standard most reputable vendors publish for BPC-157 specifically. Below 95%, a meaningful fraction of fragments and degradation products is present.

Mass spec confirmation matches the expected molecular weight (1,419.55 Da for BPC-157 free peptide, slightly higher for the acetate or arginate salt forms) and verifies the molecule is BPC-157 rather than a related sequence mislabeled. Vendors that decline to share a COA on request are flagged in community sourcing reviews as a quality concern.

Documented combinations

The most documented combination is BPC-157 with TB-500 (Thymosin Beta-4). Per the preclinical and community protocol literature, the two peptides target healing through different mechanisms — BPC-157 promotes vascular and cellular regeneration via NO system modulation and growth factor expression, while TB-500 acts on actin remodeling and cell migration. Combination protocols typically run BPC-157 at 250 to 500 mcg daily with TB-500 at 2 to 5 mg twice weekly, dosed independently rather than mixed in the same syringe.

GHK-Cu (copper peptide) is documented in some recovery-focused protocols alongside BPC-157, particularly for skin and connective tissue applications. The pairing is community-reported; no peer-reviewed combination studies exist.

KPV (a tripeptide derived from alpha-MSH) is occasionally combined with BPC-157 in gut-focused protocols, with both peptides targeting GI inflammation through separate pathways. This combination is more recently documented and has limited literature support.

FAQ

How long does BPC-157 take to start working?

Community protocol surveys describe noticeable pain reduction and improved mobility within 5 to 10 days of starting daily administration at 250 to 500 mcg. Tendon, ligament, and connective-tissue improvements are typically reported over 2 to 8 week cycles. These timelines come from individual user reports and animal research rather than controlled human trials, and individual response varies.

Can BPC-157 be taken orally?

The acetate form has approximately 3% oral bioavailability for systemic effects per He et al. 2022, but delivers a meaningful local dose to the gastrointestinal mucosa and is documented in oral protocols for gut-targeted applications. The arginate form claims approximately 90% oral bioavailability per patent literature, though independent human pharmacokinetic confirmation has not been published. For systemic musculoskeletal effects, subcutaneous injection remains the standard administration route.

Should BPC-157 be cycled on and off?

Cycling is convention rather than requirement. Community protocol surveys describe 4 to 12 weeks on followed by similar off periods. The rationale is not established in clinical literature; preclinical animal studies have used continuous administration without documented adverse effects, but long-term human safety data is absent.

Is BPC-157 banned by WADA?

Yes. BPC-157 is on the World Anti-Doping Agency Prohibited List under category S0 (non-approved substances), banned at all times in and out of competition for athletes subject to anti-doping testing.

What is the half-life of BPC-157?

Published preclinical pharmacokinetic studies describe a plasma half-life of less than 30 minutes. The peptide clears from circulation rapidly. Healing-related downstream effects (growth factor signaling, anti-inflammatory cascades) continue after the peptide itself is cleared.

Is BPC-157 the same as Pentadeca Arginate?

Pentadeca Arginate (PDA) is a marketing name used by some compounding pharmacies for BPC-157 Arginate, the arginine salt form. The 15-amino-acid peptide sequence is identical to standard BPC-157; the difference is the counter-ion. PDA's documented advantage is improved stability for oral administration.